Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

MK-4409

Non-covalent oxazole FAAH inhibitor (IC50 11 nM) made by Merck and studied in rat pain models; no commercialisation found.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₂H₁₇ClFN₃O₂S

CAS 1207745-58-1

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
441.90 g/mol

Updated on

In plain terms

MK-4409 blocks the enzyme that destroys anandamide, which raises the endocannabinoids the body makes naturally. Made by Merck, it reduced pain hypersensitivity in rat models. It was not marketed and no study in humans was found.

Receptors and activity

Target network

FAAHInhibitorIC50 = 11 nM · humanhuman FAAH lysate, IC50 11 nM (rat: 11 nM); non-covalent, reversible inhibition; table 1 of the article
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to MK-4409: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of MK-4409.

Brain, side view
Body, front view
Blood

FAAHFAAH found in 7 regions of the body

  1. CortexpresentCortical pyramidal neurons1
  2. Basal gangliapresentStriatal neurons1
  3. HypothalamuspresentPresent in hypothalamic nuclei1
  4. CerebellumpresentPurkinje cells and cerebellar layers1
  5. BrainstempresentInferior olivary nuclei1
  6. Adipose tissuepresentExpressed in mature adipocytes2
  7. BonepresentPresent on osteoclasts3

Cited values

  1. FAAHInhibitorIC50 = 11 nM · human66 out of 100

    Chobanian et al., ACS Med Chem Lett 2014 (full text PMC4060928, table 1) (new tab) · human FAAH lysate, IC50 11 nM (rat: 11 nM); non-covalent, reversible inhibition; table 1 of the article

  2. hERG channel ([35S]MK-499 binding)Binding (function not established)Ki = 1.3 µM32 out of 100

    Chobanian et al., ACS Med Chem Lett 2014 (full text PMC4060928, table 1) (new tab) · [35S]MK-499 displacement; off-target measured in table 1; functional effect not established

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

MK-4409 is a fatty acid amide hydrolase (FAAH) inhibitor designed by Merck Research Laboratories to act in pain models by an indirect route: preventing the breakdown of anandamide rather than directly activating CB1. Chobanian and colleagues describe in 2014 the optimisation of a screening hit (a pyrazole) into a non-covalent, reversible oxazole compound: IC50 11 nM on human and rat FAAH, lower hERG binding (Ki 1,254 nM) and no notable inhibition of the vesicular monoamine transporter (EC50 above 20,000 nM) that the pyrazole analogues showed. In rats, given orally, it reduced complete Freund's adjuvant-induced allodynia at 10 and 30 mg/kg (49 to 51% then 70 to 71% reversal) to a level comparable to naproxen and, in a spinal nerve ligation model, produced about 50% reversal of allodynia at 3 mg/kg with no effect on the rota-rod up to 100 mg/kg, where URB597 needed 21 mg/kg (Chobanian et al. 2014). The authors conclude that the pharmacokinetic parameters supported development of a once-daily compound in humans; no data in humans were found. For class context, a phase 1 study of another FAAH inhibitor, BIA 10-2474, led to the death of one volunteer and neurological symptoms in four others; the cause is unknown and a hypothesis of inhibition of several lipases not targeted by a selective FAAH inhibitor has been put forward (van Esbroeck et al. 2017). Nothing of the kind is reported for MK-4409.

History

Source
An entirely synthetic compound with no natural occurrence. It comes from a medicinal chemistry programme at Merck Research Laboratories (Chobanian et al. 2014); no commercialisation was found.

Origin

Research tool

No biological pathway: MK-4409 is a synthetic compound, an oxazole substituted with a pyridine thioether, a pyridine bearing a tertiary alcohol and a fluorophenyl, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

MK-4409 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
2-[5-[5-[(5-chloro-2-pyridinyl)sulfanyl]-2-(4-fluorophenyl)-1,3-oxazol-4-yl]-2-pyridinyl]propan-2-ol
Other names
MK4409 · MK 4409

Identifiers

Formula
C₂₂H₁₇ClFN₃O₂S
CAS
1207745-58-1
InChIKey
DBZMCSVIITXLCC-UHFFFAOYSA-N
SMILES
CC(C)(C1=NC=C(C=C1)C2=C(OC(=N2)C3=CC=C(C=C3)F)SC4=NC=C(C=C4)Cl)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.